Deletion of PTENP1 pseudogene in human melanoma.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

52 citing papers in PubMed, 97 citations in OpenAlex.

1. Functional roles and clinical implications of pseudogenes signatures as emerging biomarkers in cancer.Discover oncology · 2026
   Review
2. From Genomic Fossils to Functional Elements: The Evolving Story of Pseudogenes.Advanced genetics (Hoboken, N.J.) · 2025
   Review
3. Pseudogenes in the carcinogenesis: epithelial-to-mesenchymal transition process and cancer initiating cells.Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology · 2025
   Review
4. Cancers · 2023
   Review
5. Mechanisms Controlling MicroRNA Expression in Tumor.Cells · 2022
   Review
6. Molecular Mechanisms of lncRNAs in the Dependent Regulation of Cancer and Their Potential Therapeutic Use.International journal of molecular sciences · 2022
   Review
7. Prospects of Non-Coding Elements in Genomic DNA Based Gene Therapy.Current gene therapy · 2022
   Review
8. Metastatic EMT Phenotype Is Governed by MicroRNA-200-Mediated Competing Endogenous RNA Networks.Cells · 2021
   Review
9. Racial disparity in prostate cancer in the African American population with actionable ideas and novel immunotherapies.Cancer reports (Hoboken, N.J.) · 2021
   Review
10. PTENP1-AS contributes to BRAF inhibitor resistance and is associated with adverse clinical outcome in stage III melanoma.Scientific reports · 2021
    Article
11. Nradd Acts as a Negative Feedback Regulator of Wnt/β-Catenin Signaling and Promotes Apoptosis.Biomolecules · 2021
    Article
12. Pseudogenes as Competitive Endogenous RNAs: Target Prediction and Validation.Methods in molecular biology (Clifton, N.J.) · 2021
    Article
13. Long Non-Coding RNA CD27-AS1-208 Facilitates Melanoma Progression by Activating STAT3 Pathway.Frontiers in oncology · 2021
    Article
14. Global gene methylation profiling of common warts caused by human papillomaviruses infection.Saudi journal of biological sciences · 2021
    Article
15. LncRNAs in Cancer: From garbage to Junk.Cancers · 2020
    Review
16. Non-coding RNAs in aortic dissection: From biomarkers to therapeutic targets.Journal of cellular and molecular medicine · 2020
    Review
17. The Complex Landscape ofCold Spring Harbor perspectives in medicine · 2020
    Review
18. Identification of Potential Diagnostic and Prognostic Pseudogenes in Hepatocellular Carcinoma Based on Pseudogene-miRNA-mRNA Competitive Network.Medical science monitor : international medical journal of experimental and clinical research · 2020
    Article
19. LAceModule: Identification of Competing Endogenous RNA Modules by Integrating Dynamic Correlation.Frontiers in genetics · 2020
    Article
20. Re-recognition of pseudogenes: From molecular to clinical applications.Theranostics · 2020
    Review

Corrections and comments

• Comment on
  Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma.2004

Authors and funding

9 authors at 3 institutions in 1 country.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as